MetaCap

Lifecore Biomedical Inc. (LFCR)

NASDAQ: LFCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.39+0.02 (+0.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LFCR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$242.22M
EPS (TTM)
-$1.27
52-week range
3.63 – 8.98
Day range
6.37 – 6.39
Volume / Avg
218.74K / 414.71K
Beta
—

52-week range

$3.63$8.98

LFCR stock today

Shares of Lifecore Biomedical (LFCR) finished higher on Nov 20 at $6.39, a gain of 0.31% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 28.8% below their 52-week high of $8.98, set on Jan 27, 2026 and 76.0% above the 52-week low of $3.63, in the middle of the past year's range. LFCR is down 21.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 16.4%.

Lifecore Biomedical has posted a net loss over the last twelve months (EPS of -$1.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lifecore Biomedical

Company profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Paul Josephs
Headquarters
Chaska, MN
Employees
382

Financial highlights

Full financials

In fiscal 2025, Lifecore Biomedical generated $128.9 million in revenue, up 0.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Lifecore Biomedical reported a net loss of $38.7 million, compared with net income of $12.0 million a year earlier. Gross margin was 31.3% (down from 32.6%) and operating margin -13.4%.

Lifecore Biomedical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$128.87M$128.26M$103.27M$111.27M$100.87M
Growth+0.47%+24.20%-7.19%+10.31%-36.98%
Net income$-38.72M$12.01M$-99.56M$-116.72M$-32.29M
EPS (diluted)$-1.27$0.33$-3.32$-3.97$-1.10

Analyst forecast

Forecast

Consensus (5 analysts)

hold

Avg. price target

$6.28-1.72%

  • Strong buy 0
  • Buy 0
  • Hold 5
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.08 vs $-0.30
Surprise
-260.00%

LFCR news

All LFCR news

Lifecore Biomedical peers

Health Care sector
LFCR peer companies
CompanyPrice% ChgMarket capCompare
CAMPCAMP4 Therapeutics Corporation3.79-5.25%$237.84Mvs LFCR
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs LFCR
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs LFCR
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs LFCR
ALTAltimmune Inc.1.33-5.67%$258.80Mvs LFCR
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs LFCR
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs LFCR
IMRXImmuneering Corporation Class A3.38-2.03%$218.90Mvs LFCR

Indexes, lists and sector

Lifecore Biomedical stock FAQ

What is Lifecore Biomedical's stock price today?

LFCR last traded at $6.39 as of Nov 20, 4:00 PM EST, up 0.31% on the day. Prices are delayed at least 15 minutes.

Who is Lifecore Biomedical's CEO?

Mr. Paul Josephs is the chief executive officer of Lifecore Biomedical Inc., which has about 382 employees.

What is the LFCR 52-week high?

The 52-week high for LFCR is $8.98 and the 52-week low is $3.63. The stock is currently 28.8% below its high.

Compare LFCR